As per our research report, the size of the global histone deacetylase inhibitors market is predicted to be worth USD 152 Million by 2027, growing at a CAGR of 8.11% from 2022 to 2027.
Histone Deacetylase Inhibitors are classified in product such as DEAE-Dextron, calcium phosphate, Activated dendrimers, etc., and the equipment-liposomes, microinjection, and laserfection. HDACs play an important role in the regulation of gene expression. HDACs are present in a high amount in many types of tumor.
The adoption of innovative technology advancements, improvements in the healthcare infrastructure, and the rapid growth rate in government initiatives in pharmaceutical & biotechnology companies for the drug developments greatly influence the global histone deacetylase inhibitors market growth.
Collaborations between the companies & lunch of innovative products are increasing the growth of the market. An increase in cancer patients and other illnesses with effective results in treatment is driving the market of HDAC market. Investment in research and development activities surges the market. HDAC reduces the rate of angiogenesis & sincreases the immune response, providing scope for market growth.
A growing number of people suffering from cancer is a crucial factor propelling the market demand. Increasing support from the government and the rise in investments in research and development in the cancer treatment field drive the demand of the market. Huge demand for achieving maximum productivity with very less cost is the major factor responsible for boosting up the market growth. The manufacturers of histone deacetylase inhibitors collaborate with other companies, which is also one of the factors leading to market growth.
Need to make better changes in the effectiveness of new treatments, growing mergers and collaborations also accelerate market growth. The rise in the common increase of cancer is also bolstering the market. Also, research and development related to disorders or nerves and other diseases are driving the market forward. Funds from the government and other organizations are also boosting the market. Pharmaceutical industries spending huge amounts of money on R&D and growing prevalence for diagnosing the disease at an early stage are ascribed to bolster the market's growth rate.
Lack of reimbursement policies in undeveloped countries is hindering the global Histone deacetylase inhibitors market growth.
Lack of knowledge among the people may limit the growth rate of this market. Strict rules and guidelines to be followed for the product to be approved are also the factors that restrain the market growth. Less awareness in the patients for the treatment of cancer & chronic diseases are hampering the market growth. The rising value of raw material required for the production & manufacturing of HDACs has reduced the market growth for the future. HDACs side effects such as toxicity after consumption are also a factor impeding the demand of the market. Some factors that influence the HDACs market are less skilled professionals in well-developed countries.
Impact of COVID-19 on the global histone deacetylase inhibitors market:
The novel coronavirus (COVID 19) has strained severe health risks to humans and the economy. By March 2020, the virus has spread to every country across the globe. In general, HDAC inhibitors are used by kidney and diabetic patients to fight the disease-causing cells. The use of HDAC inhibitor, romidepsin, effectively stops the virus from entering the body. The U.S Food and Drug Administration (FDA) approves HDAC inhibitors treatment for pulmonary fibrosis and essential molecular mechanisms in executing the pathological procedures in recovered COVID 19 patients. Panobinostat is one HDAC inhibitor that can act as a preventive drug against COVID 19. HDAC presents one of the most promising viral drugs used in treating the infectious virus. As of now, six HDAC anticancer drugs were approved by the FDA. In the current situations, the EMA-approved SARS-CoV-2 off-labeled HDAC inhibitor drugs are reused to restrain or avoid the host-virus interaction. The HDAC valproic acid, which is available for treating those who are diagnosed with epilepsy. The drug is remodeled for patients with COVID 19 to avoid acute respiratory distress syndrome (ARDS). The valproic acid helps both COVID-19 infection and in those who are infected decreases the ARDS along with other aimed organ damage, reducing hospitalizations and death.
Market Size Available
2021 to 2027
2022 to 2027
By Class, Application, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This market research report on Global Histone Deacetylase Inhibitors Market has been segmented based on class, application, and region.
Histone Deacetylase Inhibitors Market - By Class:
Histone Deacetylase Inhibitors Market – By Application:
Histone Deacetylase Inhibitors Market – By Region:
Geographically, the North American regional market accounted for the largest share in the global market. It is expected to retain its lead by 2025. Higher adoption rates in this region are the cause attributable to the observable trend mentioned above. Europe comes second by market share. It is, however, anticipated to experience slow growth in the forecast period.
Europe stands second, followed by North America. This region is likely to have a high CAGR value during the period and is estimated to reach a million-dollar USD. In the European region, the UK is expected to lead the market. The adoption of advanced technology in the healthcare centers is propelling the demand of the market.
The Asia Pacific is poised for a robust growth trajectory in the forecast period. China will spearhead this growth spurt. Latin America and MEA continue to tail these leading regional markets in the forecast period.
KEY MARKET PARTICIPANTS:
Some of the notable companies leading the global histone deacetylase inhibitors market profiled in the report are Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celeron Therapeutics, Envivo Pharmaceuticals, and Pfizer, Inc.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Class I HDACs
5.1.3 Class II HDACs
5.1.4 Class III HDACs
5.1.5 Y-o-Y Growth Analysis, By Class
5.1.6 Market Attractiveness Analysis, By Class
5.1.7 Market Share Analysis, By Class
5.2.3 Central Nervous System Disorders
5.2.4 Other Diseases
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Class
188.8.131.52 By Application
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Class
18.104.22.168 By Application
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Class
188.8.131.52 By Application
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Acetylon Pharmaceuticals
8.3 Celleron Therapeutics
8.4 Envivo Pharmaceuticals
8.6 Merck & Co.
8.8 Eisai Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.